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Abstract 
Background: The optimal long-term antithrombotic regimen for patients after successful catheter-based 
atrial fibrillation (AF) ablation is not well-defined. Presently, practice variation exists and the benefits of 
oral anticoagulation (OAC) over antiplatelet therapy across the entire spectrum of stroke risk profile 
remain undefined in the post-ablation population. To date, there are no randomized trials to inform 
clinicians on this therapeutic question.  
 
Objective: To assess whether rivaroxaban is superior to acetylsalicylic acid (ASA) in reducing the risk of 
clinically overt stroke, systemic embolism, or covert stroke among patients without apparent recurrent 
atrial arrhythmias for at least one year after their most recent AF ablation procedure.  
 
Methods/Design: A prospective, multicenter, open-label, randomized trial with blinded assessment of 
outcomes is underway (NCT02168829). Atrial fibrillation patients with at least 1 stroke risk factor (as 
defined by the CHA2DS2-VASc score) and without known atrial arrhythmia recurrences for at least 12 
months after ablation are randomized to rivaroxaban 15 mg or ASA 75-160 mg daily. The primary 
outcome is a composite of clinically overt stroke, systemic embolism, and covert stroke based on brain 
magnetic resonance imaging (MRI). Key secondary outcomes include: major bleeding outcomes, 
intracranial hemorrhage, transient ischemic attack, neuropsychological testing, quality of life, and an 
economic analysis. Subjects will be followed for 3 years. The estimated overall sample size is 1572 
subjects (786 per arm).  
 
Discussion: The OCEAN trial is a multicenter randomized controlled trial evaluating two antithrombotic 
treatment strategies for patients with risk factors for stroke after apparently successful AF ablation. We 
hypothesize that rivaroxaban will reduce the occurrence of clinically overt stroke, systemic embolism, 
and covert stroke when compared to ASA alone.  
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Background 
 Catheter-based atrial fibrillation (AF) ablation is a useful and effective rhythm-control 
therapy for patients with symptomatic AF. Multiple randomized trials have demonstrated that 
ablation is superior to anti-arrhythmic drugs in reducing AF recurrence and improving quality of 
life, particularly for those in whom drugs are ineffective.
1-4 
Accordingly, ablation is an important 
therapy for patients with symptomatic AF, as reflected in current guidelines and by the 
considerable rise in procedural volumes over the past decade.
2,6,7
 
 
 The impact of AF ablation on stroke prevention is not well-defined. Ongoing trials which 
address the prognostic impact of rhythm-control therapies including AF ablation, such as the 
Early Treatment of Atrial Fibrillation for Stroke Prevention trial (EAST; NCT01288352), 
Catheter Ablation vs. Anti-arrhythmic Drug Therapy for Atrial Fibrillation trial (CABANA; 
NCT00911508), and Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug 
Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-
ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation (RAFT-AF; 
NCT01420393) will provide insight on this question. Yet, it is not uncommon for clinicians 
and/or patients to consider discontinuation of oral anticoagulation (OAC) after ablation. For 
many patients, the desire to stop anticoagulation is a prime motivation for ablation.  Current 
guidelines, however, recommend continuation of OAC based on clinical risk scoring, 
irrespective of procedural outcome.
2,3
  Observational studies suggested that the risk of stroke or 
transient ischemic attack (TIA) among patients who discontinued OAC after "successful" AF 
ablation could be as low as 0.7% per year.
9-18 
Although this seems to support the notion that the 
embolic risk of AF patients with successful ablation may be low enough to justify 
discontinuation of OAC, these studies are limited by short follow-up periods and their 
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retrospective, non-randomized design which make them susceptible to confounding.
 9-18 
As well, 
these studies had low event rates since they primarily included patients with few medical co-
morbidities.
9-18 
Presently, there are no randomized trials to inform clinicians on whether 
successful AF ablation sufficiently reduces patients' risk of stroke to a point where long-term use 
of OAC is obviated, particularly at a time when non-vitamin K oral anticoagulants (NOAC) are 
widely used in clinical practice.  
Current AF guidelines generally support continuation of OAC after apparently successful 
catheter ablation, but they reflect the paucity of high-quality data in inform practice. The 
Canadian guidelines recommend that OAC should be discontinued after ablation if the patient's 
long-term risk of stroke is low and in the presence of sustained normal sinus rhythm.
2 
Recognizing the absence of randomized controlled data on this topic, European AF guidelines 
recommend that the decision to continue with OAC should follow general anticoagulation 
recommendations regardless of rhythm status.
3 
Similarly, the 2017 Heart Rhythm 
Society/European Heart Rhythm Society/ European Cardiac Arrhythmia Society/Asia Pacific 
Heart Rhythm Society/Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología 
(HRS/EHRA/ECAS/APHRS/SOLAECE) expert consensus statement on catheter and surgical 
ablation of AF stated that the decision to continue with OAC at more than 2 months post-ablation 
should be based on the patient’s stroke risk profile as opposed to the perceived success or failure 
of the procedure.
4
  Finally, performing catheter ablation to restore sinus rhythm for the "sole 
intent of obviating the need for anticoagulation" is a class III recommendation (level of evidence: 
C) in the 2014 American College of Cardiology Foundation/American Heart Association/Heart 
Rhythm Society (ACCF/AHA/HRS) guidelines.
5
 The cautious wording of these 
recommendations underscores the lack of data to inform clinicians on the optimal long-term 
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antithrombotic management for patients after AF ablation. In fact, the new 2017 
HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical 
ablation of AF lists the management of OAC post-AF ablation as the number one unknown 
question in our field.
4
  In the 2016 European Society of Cardiology AF guidelines and the 
Venice Chart international consensus statement on AF ablation, the optimal long-term 
management of OAC after ablation is a "key unresolved question".
3,19
 
 The Optimal Anti-Coagulation for Enhanced Risk Patients Post-Catheter Ablation for 
Atrial FibrillatioN trial (OCEAN trial; NCT02168829) is a multicenter randomized controlled 
trial designed to examine the optimal method of stroke prevention for patients after successful 
AF ablation who are at risk for stroke based on their CHA2DS2-VASc (congestive heart failure, 
hypertension, age ≥75 years (2 points), diabetes mellitus, previous stroke/transient ischemic 
attack (TIA) (2 points), vascular disease, age 65–74 years, sex class (female)) score. Among 
patients without apparent atrial arrhythmia recurrences for at least 12 months after AF ablation, 
we hypothesize that the use of rivaroxaban will reduce the rate of stroke, systemic embolism, and 
covert embolic stroke (defined by cerebral magnetic resonance imaging (MRI)) when compared 
to acetylsalicylic acid (ASA). 
 
Methods 
Study design 
 The OCEAN trial is a multicenter, 2-arm randomized controlled trial with a prospective, 
randomized, blinded endpoint (PROBE) design. It is enrolling subjects at risk for stroke and who 
have not had clinically apparent atrial fibrillation, flutter, or tachycardia (AF/AFL/AT) 
recurrences for at least 12 months after their most recent paroxysmal, persistent, or longstanding 
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persistent AF ablation procedure. Eligible and consenting subjects will be randomized in a 1:1 
ratio to OAC therapy (rivaroxaban 15 mg daily) or single antiplatelet therapy (ASA 75-160 mg 
daily). Randomization with concealed allocation will be performed using blocked cells of 
varying sizes using web-based software (Dacima, Montreal, Canada). Outcomes will be 
adjudicated by personnel who are blinded to subjects' randomization status. All sites will obtain 
approval from their respective ethics committees and the study procedures will be performed 
with the principles of Good Clinical Practice and the Declaration of Helsinki. The authors are 
solely responsible for the design and conduct of this study, all study analyses, the drafting and 
editing of the paper and its final contents 
 
Study setting and timeline 
 This is a multicenter trial involving AF ablation centers in Canada, Germany, the United 
Kingdom, Belgium, Australia, and China. As of Dec 3, 2017, 14 Canadian centers and 1 Chinese 
site have been activated and 219 subjects are enrolled. We aim to complete enrollment in 24 
months and subjects will be followed for 36 months.  
 
Funding 
 The OCEAN trial is funded by a grant from the Canadian Stroke Prevention Intervention 
Network (C-SPIN). The C-SPIN network is a funding initiative by the Canadian Institutes of 
Health Research (CIHR). In addition, the trial is supported by unrestricted research grants from 
Bayer and Biotronik.  
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Study Population 
 Written informed consent will be obtained from each subject. For a subject to be eligible 
for study enrollment, at least 12 months must have elapsed after his/her last catheter ablation for 
AF without evidence of clinically apparent atrial arrhythmia recurrence. Having no "clinically 
apparent atrial arrhythmia recurrence" is defined by the absence of ≥30 seconds of AF/AFL/AT 
in: (i) at least one 24-hour Holter and ECG within the first 2-6 months after the last ablation 
procedure, and (ii) at least one 24-hour Holter and ECG beyond 6 months after the last ablation. 
If the last Holter and ECG were not performed within 2 months prior to study enrollment, 
subjects must undergo an ECG and a Holter (preferably 48-hour) demonstrating absence of ≥30 
seconds of AF/AFL/AT (Figure 1). Given that prolonged rhythm monitoring is not available for 
all subjects after AF ablation, this screening approach provides a pragmatic definition of "no 
arrhythmia recurrence" in our study. Subjects who remain treated with anti-arrhythmic drugs for 
≥12 months after their most recent ablation procedure are eligible for study enrollment. 
However, we anticipate that most, if not all, subjects in this trial will not be treated with anti-
arrhythmic drugs at the time of study enrollment. This trial will enroll subjects with CHA2DS2-
VASC scores of ≥1. Subjects with a CHA2DS2-VASC score of 1 on the basis of female sex or 
vascular disease alone are required to have at least one additional risk factor to be eligible for 
inclusion. This entry criterion is chosen to enrich a patient cohort who otherwise is at lower risk 
for stroke relative to the general AF population.
9,20  
Subjects with ischemic or non-ischemic 
cardiomyopathy are eligible for study enrollment unless they have prosthetic valves, mitral valve 
repair, or rheumatic mitral stenosis. Furthermore, our study eligibility criteria does not include a 
cut-off for left atrial size. The full inclusion and exclusion criteria are listed in Table 1.  
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Interventions 
 Subjects will be randomized in a 1:1 ratio to OAC or single antiplatelet therapy.  The 
study flow chart is outlined in Figure 2. 
 
NOAC therapy 
In the intervention arm, subjects are treated with rivaroxaban 15 mg daily. The rationale 
for choosing a rivaroxaban dose of 15 mg was supported by pharmacokinetic and clinical trial 
data which suggested that this dose could be safely used in the AF population without a 
discernible signal of increased harm or decreased efficacy.
21-23
 Additional details on the rationale 
for the choice of this rivaroxaban dose are discussed in the Supplementary Appendix.  No dose 
adjustment will be performed for patients with creatinine clearance of 30-49 ml/min, although it 
is expected that the number of patients with creatinine clearance of <50 ml/min will not be 
substantial in a post-ablation population.  If the subject cannot tolerate rivaroxaban due to side 
effects, another NOAC agent may be prescribed. If dabigatran is prescribed, the dose will be 110 
mg twice daily. Given the absence of evidence to support the use of apixaban and edoxaban at 
reduced doses for subjects with preserved renal function, standard doses of these drugs will be 
prescribed if they are used in this trial.   
 
Single antiplatelet therapy 
 Subjects randomized to the control arm are treated with ASA at 75-160 mg daily. This 
range is provided to accommodate for differences in ASA dosing in various countries. It is 
expected that most patients will receive 81 mg daily. Since all of the patients in this trial will 
have one or more risk factors for stroke and a significant proportion will have other vascular 
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disease, we felt that the comparator arm should use antiplatelet therapy. No antiplatelet therapy is 
only suggested in guidelines for those patients with no risk factors for stroke.
3, 24
  If the subject is 
intolerant or allergic of ASA, no other antiplatelet agent will be substituted unless there is a 
clinical need to do so (e.g. PCI or ACS).   
 
Management of the need for temporary oral anticoagulation and/or antiplatelet therapy in each 
of the randomization arms 
 It is anticipated that patients may undergo coronary intervention procedures electively or 
in the setting of an acute coronary syndrome which would require temporary adjustments in 
antiplatelet therapy.  Furthermore, some patients will experience recurrences of AF for which 
cardioversion may have to be performed with more intensive oral anticoagulation.  In both of 
these cases, the protocol outlines specific measures for management to minimize crossovers and 
disparity in patient treatment.  These are outlined in the Supplementary Appendix. 
 If a patient undergoes repeat catheter ablation for AF, the patient will be censored at that 
point in time and exited from the study.  Subjects who undergo ablation for arrhythmias other than AF 
(such as supraventricular tachycardia, right atrial flutter, ventricular arrhythmia, left atrial 
flutter/tachycardia not involving the pulmonary veins) will not be exited from the trial. 
 
Assessments: 
Brain MRI 
 All subjects will undergo brain MRI scans at 3 time points: (i) prior to randomization, (ii) 
12 months, and (iii) 36 months to detect covert strokes. Brain MRI scanning will be performed 
according to study specified protocols including diffusion-weighed MRI (DW-MRI) and T2 
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weighed fluid attenuated recovery (FLAIR) imaging (Supplementary Appendix). These scans 
will be read by core lab personnel blinded to treatment allocation (University of Calgary, 
Calgary, Alberta, Canada). The MRI results will not be routinely disclosed to the investigators or 
subjects. In the case of urgent unexpected MRI findings (like a brain tumor), neuro-radiology 
experts at the core laboratory will make recommendations to the coordinating center which will 
then inform the appropriate site. 
 
Implantable loop recorder  
 In a pre-specified sub-study, 500 subjects will undergo insertion of an implantable loop 
recorder (ILR) with automated AF detection software (BioMonitor 2.0®, Biotronik, Germany). 
This technology provides continuous arrhythmia monitoring and allows us to examine the 
relationship between AF recurrence and burden to subjects' long-term risk of clinical or covert 
stroke after ablation. Insertion and programming of the ILRs will be performed using 
standardized guidelines. All ILR data will be collected by remote monitoring and collected in a 
core lab (University of Ottawa, Ottawa, Canada) for independent adjudication by cardiologists 
who are blinded to treatment allocation. Results of the ILR will not be disclosed to investigators 
or subjects except for the occurrence of serious, non-AF arrhythmias (e.g. sustained ventricular 
tachycardia).  
 
Primary outcome 
 The primary outcome is a composite of all clinically overt stroke
25
, systemic embolism
25
, 
and incident covert stroke as detected by cerebral MRI.  It is assumed that the direction of 
treatment effect for each of the components of the primary outcome will be the same. Stroke is 
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defined as a sudden, focal neurologic deficit resulting from a presumed cerebrovascular cause 
that is not reversible within 24 hours and not due to a readily identifiable cause, such as a tumor 
or seizure.
25
 Brain imaging is sought in each case to help distinguish hemorrhagic from ischemic 
stroke. Subjects dying from any cause within 30 days of the onset of stroke are regarded as 
having fatal stroke.
25 
Non-central nervous system systemic embolism is defined as abrupt 
vascular insufficiency associated with clinical or radiologic evidence of arterial occlusion in the 
absence of other likely mechanisms (eg, trauma, atherosclerosis, or instrumentation).
25
 In the 
presence of atherosclerotic peripheral arterial disease, the diagnosis of embolism to the lower 
extremities requires angiographic demonstration of abrupt arterial occlusion.
25 
Covert stroke is 
defined as the presence of one or more lesions >15 mm
26,27 
detected between the baseline, and 
one or more of the one year, and final (three year) MRI on T2 weighted and/or FLAIR MRI 
scanning protocols.  Rationale for the 15 mm cutoff is provided in the Supplementary Appendix.   
 
Secondary outcomes 
 Each component of the primary outcome will be assessed as a secondary outcome. In 
addition, we will assess the incidence of major bleeding, clinically relevant non-major bleeding, 
minor bleeding, and their composite as defined by the International Society of Thrombosis and 
Haemostasis (ISTH).
28,29 
Other secondary outcomes include: clinically-overt intracranial 
hemorrhage (ICH); microbleeds as detected by MRI
30
; transient ischemic attack (TIA) defined as 
presence of a new focal neurologic deficit thought to be vascular in origin with signs or 
symptoms lasting <24 hours without evidence of infarction (assessed with brain imaging)
31
; all-
cause mortality; net clinical benefit based on reduction in stroke/TIA rate compared to major 
bleeding events; occurrence of non-primary endpoint MRI changes from baseline to final scan 
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such as: total number of new MRI lesions with sizes of >3 mm, >5 mm, >15 mm, and >20 mm; 
correlation of AF burden/recurrence to occurrence of clinical or covert stroke; 
neuropsychological testing (Montreal cognitive assessment (MoCA) and the Modified mini 
mental state exam (3MSE)) at baseline and at 3-year follow-up; quality of life with the EQ-5D-
5L questionnaire and the visual analog scale at baseline, 1-year, and 3-year follow-up; and cost 
utilization/effectiveness analysis. 
 
Outcome adjudication 
 Outcomes will be adjudicated by a clinical events committee, consisting of cardiologists 
and neurologists who are blinded to subjects' treatment assignment. 
 
Planned analyses 
 Descriptive statistics including 95% confidence intervals will be calculated for baseline 
variables using means, medians, standard deviations and interquartile ranges for continuous 
outcomes, and rates and proportions for discrete outcomes for each treatment arm.   
 The primary analysis will be conducted with the intention-to-treat principle. For the 
primary outcome, the OAC versus ASA arms will be compared using the chi-square test. Time-
to-event analysis for the primary outcome will not be performed since the exact timing of covert 
stroke cannot be determined based on the baseline, 12-month, and 36-month MRI scans alone. A 
secondary, on-treatment analysis will be conducted to account for subjects who crossed over or 
discontinued their assigned therapy during the study. A subject will be classified as crossover if 
he/she permanently changes to the other treatment arm for any reason other than those 
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specifically defined in the protocol as a short-term change in treatment (e.g. those who 
underwent PCI or cardioversion). A permanent change is defined as >3 months.  
 An interim analysis for efficacy is planned after all subjects have completed their 1-year 
MRI scans. This would occur at approximately year 3 of the study.  We assume that all of the 
patients are recruited into the study in a stepped uniform fashion, with increasing enrollment as 
more centers are activated in the study, and that study events occur in a uniform fashion over the 
3 year follow-up period. It is estimated that approximately 55% of the expected events in the 
study will have occurred at the time of interim analysis, but the actual level of information will 
be determined at that time.  Considering a flexible monitor perspective for the planned group 
sequential method, and using the Lan and DeMets error spending approach, with O’Brien-
Fleming type boundaries, the alpha values for the interim and final analyses will be determined 
preserving the overall two-sided type I error rate of 0.05.  An independent Data Safety and 
Monitoring Board (DSMB) is in place which will evaluate the results and provide 
recommendations on trial continuation and sample size.  
 
Data collection and management 
 After the baseline and randomization visit, subjects will be seen at in-person follow-up 
visits at 6 and 12 months and then annually. An exit visit will occur at study end. The following 
information will be collected at each visit: medical history; stroke; systemic embolism; bleeding 
events; medications; and 12-lead electrocardiograms. It is recommended that all patients undergo 
annual 48-hour Holter monitoring as standard of care. Quality of life assessment will occur at 
baseline, 12 months, and 36 months. Neuropsychological testing will be performed at baseline 
and 36 months.  
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 The University of Ottawa Heart Institute (UOHI) Cardiovascular Methods Center is the 
coordinating center for all aspects of the OCEAN trial. Specifically, it will be responsible for the 
randomization process and for receiving, editing, processing, analyzing, and storing data 
generated in this trial. Data entry will be electronic and web-based. All endpoint outcomes will 
be assessed by blinded, independent adjudicators. Study safety oversight will be provided by an 
independent DSMB. 
 
Sample size calculation 
 An annual primary outcome rate of 3.5% per year (consisting of an annual stroke rate of 
1.6%
32
 and a covert stroke rate of 1.9% per year in the control group
33
) is assumed. This trial is 
designed as a superiority trial to demonstrate that rivaroxaban 15 mg daily will result in a 1.4% 
absolute risk reduction (40% relative risk reduction) of the primary endpoint when compared to 
ASA. This magnitude of difference was estimated from the MRI sub-study of the Apixaban 
versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are 
unsuitable for vitamin K antagonist treatment (AVERROES) trial which compared subjects 
treated with apixaban to those treated with ASA alone.
34   
In the subset of patients with CHADS2 
score of 0-1, the relative risk reduction was 44%. 
 
In the OCEAN trial, the planned accrual rate is 
2 years with a follow-up period of 3 years. 
We anticipate a 5.75% dropout (e.g. due to repeat ablation) and crossover rates of 1.5% 
and 3.75% for the rivaroxaban and ASA arms, respectively. Based on these assumptions, with a 
two-sided alpha of 0.05 and a power of 80%, a total sample size of 1572 patients will be required 
(786 in each arm).  
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Discussion 
 The optimal long-term OAC management for patients after successful AF ablation is 
currently unknown. In a Canadian survey, over 95% of electrophysiologists would discontinue 
OAC after successful ablation if their patients' CHADS2 score was 1 or less.
35 
In an European 
survey of electrophysiologists, 16% of them were comfortable with OAC cessation after 
successful ablation even if the patients' stroke risk were high (CHADS2≥2).
36 
Coupled with an 
acknowledged lack of evidence underpinning current guideline recommendations on this topic
2-5
, 
we believe that equipoise exists and hence justifies conduct of a randomized trial to address this 
question.  
 In addition to the more traditional clinical endpoints of stroke and systemic embolism, the 
OCEAN trial will assess if the incidence of covert stroke (as detected by brain MRI) differs 
between subjects treated with rivaroxaban versus ASA after apparently successful AF ablation. 
Covert stroke  is defined as “imaging or neuropathological evidence of brain infarction, without 
a history of acute neurological dysfunction attributable to the lesion”.37 Covert stroke may occur 
in 50-90% of patients with AF, even among those felt to be at low risk for stroke.
38-40
 In addition, 
covert stroke is estimated to be 2-7 times more common than the incidence of clinically manifest 
stroke in patients with AF.
33,38,41,42 
Although these infarctions are not immediately symptomatic, 
long-term studies suggest that such changes are related to future clinical stroke
43-45
, cognitive 
decline
46,47
, dementia
48-50
, and increased mortality.
51,52 
Thus, AF-related covert stroke as detected 
by MRI is an area of emerging importance.
53 
The OCEAN trial will afford us an opportunity to 
examine the association between AF and covert stroke and whether rivaroxaban use may alter its 
incidence when compared to ASA.  
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 Despite the strong association between AF and stroke, the mechanism by which AF 
causes stroke is undefined and is a topic of considerable interest. Classically, it is believed that 
AF leads to clot formation due to stasis of blood in the left atrium, which in turn causes stroke. 
However, studies of patients with dual chamber pacemakers had demonstrated a temporal 
dissociation between the onset of AF and the occurrence of stroke in a sizeable proportion of 
them, raising the possibility that AF may be a marker of higher stroke risk rather than being a 
primary causal driver for stroke.
54,55 
In this respect, the ILR sub-study of OCEAN will provide 
additional insight on the causal relationship between AF and stroke. It may also inform us on the 
true risk of stroke associated with infrequent atrial high rate episodes in the post-ablation 
population.
56
 
 In conclusion, the OCEAN trial is a multicenter, randomized controlled trial which 
examines if OAC will lower the risk of stroke, systemic embolism, and covert stroke amongst 
patients who have had successful AF ablation when compared to ASA. The results of this trial 
will help inform clinicians on the optimal antithrombotic regimen for post-ablation patients with 
risk factors for stroke.  
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Table 1.  Study Inclusion and Exclusion Criteria 
Inclusion Criteria 
1. Patient must be at least one year post-successful catheter ablation(s) for atrial fibrillation 
without evidence of any clinically apparent arrhythmia recurrence defined as all of the 
following:  No AF/AT/AFL on at least 24 hour Holter and an ECG (or equivalent) from 2-6 
months after the last ablation, AND no AF/AT/AFL on at least 24 hour Holter and an ECG 
any time after 6 months after the last ablation AND no AF/AT/AFL on at least 24 hour 
Holter and ECG 2 months before enrolment in the study.  The Holter/ECG within 2 months 
of enrolment may also serve as the Holter/ECG performed 6 months or later after the last 
ablation – see section 2.3.1.  
2. Patient must have a CHA2DS2-VASc risk score of 1 or more.  Patients in whom female sex 
or vascular disease are their sole risk factor may not be enrolled.   
3. Patient must be >18 years of age. 
4. Patient must have non-valvular AF (such as valvular prosthesis, rheumatic mitral stenosis, 
mitral valve repair) 
Exclusion Criteria 
1. Patient does not meet all of the above listed inclusion criteria. 
2. Patient is unable or unwilling to provide informed consent. 
3. Patient is included in another randomized clinical trial or a clinical trial requiring an 
insurance. 
4. Patient has been on an investigational drug within 30 days of enrolment. 
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5. Patient has been on strong CYP3A inducers (such as rifampicin, phenytoin, phenobarbital, or 
carbamazepine) or strong CYP3A inhibitors (such as ketoconazole or protease inhibitors) 
within 4 days of enrolment.   
6. Patient has creatinine clearance < 30 mL/min. 
7. Patient has bleeding contra-indication to oral anticoagulation (such as bleeding diathesis, 
hemorrhagic disorder, significant gastrointestinal bleeding within 6 months, 
intracranial/intraocular/atraumatic bleeding history, fibrinolysis within 48 hours of 
enrollment). 
8. Patient has other contraindication to oral anticoagulation or treatment with antiplatelet agent 
(such as allergy).  
9. Patient has a contraindication to magnetic resonance imaging (MRI) or is unlikely to tolerate 
due to severe claustrophobia. 
10. Patients with a contraindication to implantation of an implantable loop recorder (such as 
limited immunocompetence or a wound healing disorder).  
11. Patient has valvular atrial fibrillation (valvular prosthesis, rheumatic mitral stenosis, mitral 
valve repair). 
12. Patient has a non-arrhythmic condition necessitating long-term oral anticoagulation. 
13. Patient had a severe, disabling stroke within one year prior to enrollment or any stroke within 
14 days of enrollment. 
14. Patient with special risk factors for stroke unrelated to AF, specifically known 
thrombophilia/hypercoagulability, uncontrolled hypertension (systolic blood pressure >180 
mmHg and/or diastolic blood pressure >100 mmHg within 4 days of enrollment), untreated 
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familial hyperlipidemia, known vascular anomaly (intracranial aneurysm/arteriovenous 
malformation or chronic vascular dissection), or known severe carotid disease.  
15. Pregnancy or breastfeeding. 
16. Women of childbearing age who refuse to use a highly effective and medically acceptable 
form of contraception throughout the study. 
17. Patients who are > 85 years of age. 
18. Patients who are critically ill or who have a life expectancy <3 years. 
19. Patients for whom the investigator believes that the trial is not in the interest of the patient. 
 
AF = Atrial Fibrillation; AFL = Atrial Flutter; AT = Atrial Tachycardia; ECG = 
Electrocardiogram; MRI = Magnetic Resonance Imaging. 
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Figure 1. Minimum screening criteria for atrial fibrillation, atrial flutter, or atrial 
tachycardia prior to inclusion into the OCEAN study. 
The Holter and ECG performed within 2 months of enrolment may also serve as the Holter and 
ECG beyond 6 months post-ablation.
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Figure 2.  Study flow diagram for the OCEAN trial. 
AF= Atrial Fibrillation; AFL = Atrial Flutter; ASA = Acetylsalicylic Acid; AT = Atrial Tachycardia; ECG = Electrocardiogram; MRI 
= Magnetic Resonance Imaging. 
